Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)

Publisher： John Wiley & Sons Inc

E-ISSN： 1527-3350|61|5|1512-1522

ISSN： 0270-9139

Source： HEPATOLOGY, Vol.61, Iss.5, 2015-05, pp. : 1512-1522

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Optimization of lamivudine therapy

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 4, 2015-04 ,pp. : 748-755

John Wiley & Sons Inc

Access to resources Recommend Favorite

Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B

By  

HEPATOLOGY, Vol. 56, Iss. 1, 2012-07 ,pp. : 67-75

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 59-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

HLA‐DP, IL28B gene polymorphisms and IFN

By  

HEPATOLOGY RESEARCH, Vol. 44, Iss. 9, 2014-09 ,pp. : 1000-1007

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of hepatitis B virus subgenotype on antiviral response in nucleoside‐treated hepatitis B envelope antigen‐positive patients

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 2, 2018-02 ,pp. : 134-143

John Wiley & Sons Inc

Access to resources Recommend Favorite